the Delta, Kappa, and Delta Plus variants reduce virus neutralising potency from vaccine-induced antibodies.

Company's step-down wholly owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received approval for Oxybutynin Chloride Tablets...

The new agreements secure access to 7.6 million doses from AstraZeneca -- enough for 3.8 million people, and 10.72 million doses from Novav...

Illegal import of drugs from Bangladesh and other neighbouring countries have further added to the woes of pharmaceutical companies. Expert...

India's dependency on charity from global drug makers is making it hard for patients to access new antibiotic drugs such as bedaquiline and...

Instead, the company will focus on a cure for chronic hepatitis B, an inflammation of the liver caused by a different virus.

"TB remains a significant challenge in India, killing approximately half a million-people in 2015 alone," said Anil Koul director, CSIR-IMT...

Going against the grain: With the unique hybrid model for India, co aims at building scale & ramping up businesses.

For Infliximab, Reliance Life Sciences had completed process development, manufacturing, clinical trials in India and obtained marketing ap...

Janssen’s Remicade is the third biggest pharmaceutical brand globally with sales exceeding $8 billion last year.

With Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.

As New Scientist explains, the flu virus carries big, globular "decoy" proteins on its surface to grab our immune system's attention.

Researchers from the University of British Columbia developed the method which turns stem cells into insulin-producing cells in about six w...

Jubilant Biosys will carry out research services and deliver preclinical candidates to Janssen for potential development and commercialisat...

Indian firms need handholding, but there have been times when they were left on their own after being assigned a project.

Pharma firm Jubilant Life Sciences soared over 11% after its US-based arm inked drug discovery pact with Belgium-based Janssen Pharmaceutic...

India's bio-pharma sector may see a surge in R&D spending to about $25 billion in the next 15 years, according to a Boston Consulting Group...